Open AccessAdvances in topiramate as prophylactic treatment for migraine
Author(s) -
Hu Chuan,
Zhang Yixin,
Tan Ge
Publication year - 2021
Publication title -
brain and behavior
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.915
H-Index - 41
ISSN - 2162-3279
DOI - 10.1002/brb3.2290
Subject(s) - topiramate , migraine , medicine , adverse effect , prophylactic treatment , antiepileptic drug , epilepsy , quality of life (healthcare) , pediatrics , psychiatry , intensive care medicine , pharmacology , nursing
It is well‐known that topiramate as a kind of antiepileptic drug has been proved effective for migraine prevention in North America and Europe. However, topiramate is still viewed as an off‐label medication for migraine treatment in China, partly because of the limited evidence in Chinese patients. We summarize the effects of topiramate on the frequency, severity, quality‐of‐life, and adverse event among migraine patients, including children and adolescent in this review, so as to provide reference for Chinese doctors.